PTGX:NSD-Protagonist Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 30.97

Change

0.00 (0.00)%

Market Cap

USD 1.47B

Volume

0.89M

Avg Analyst Target

USD 49.86 (+60.99%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD133.96B 39.21 29.43
BNTX BioNTech SE

N/A

USD60.07B 13.83 10.18
REGN Regeneron Pharmaceuticals Inc

N/A

USD59.17B 9.99 7.57
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD47.16B 23.96 15.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD33.45B N/A N/A
SGEN Seagen Inc

N/A

USD31.43B 53.89 40.74
GMAB Genmab A/S

N/A

USD29.05B 74.91 8.12
ALNY Alnylam Pharmaceuticals Inc

N/A

USD24.79B N/A N/A
RPRX Royalty Pharma plc

N/A

USD23.31B 31.09 11.82

ETFs Containing PTGX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 53.62% 87% B+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.62% 87% B+ 87% B+
Trailing 12 Months  
Capital Gain 48.75% 78% C+ 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.75% 78% C+ 67% D+
Trailing 5 Years  
Capital Gain 38.07% 63% D 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.07% 62% D- 43% F
Average Annual (5 Year Horizon)  
Capital Gain 44.53% 72% C- 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.53% 72% C- 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 95.34% 30% F 17% F
Risk Adjusted Return 46.70% 74% C 64% D
Market Capitalization 1.47B 79% C+ 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.30 28% F 36% F
Price/Book Ratio 4.70 38% F 30% F
Price / Cash Flow Ratio -20.32 77% C+ 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -31.05% 77% C+ 35% F
Return on Invested Capital -35.64% 63% D 22% F
Return on Assets -16.19% 73% C 22% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.64 76% C 68% D+
Short Percent 12.41% 14% F 13% F
Beta 1.95 20% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector